Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Trial to Investigate the Third-Generation Anti-CD19 CAR T-cell Therapy in Patients with Relapsed or Refractory, CD19+ Leukemias and Lymphomas

Trial Profile

A Phase 1 Trial to Investigate the Third-Generation Anti-CD19 CAR T-cell Therapy in Patients with Relapsed or Refractory, CD19+ Leukemias and Lymphomas

Planning
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2018

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary)
  • Indications B cell lymphoma; Leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Oct 2018 According to a ZIOPHARM Oncology media release, the company have updated guidance on the timing of its response to the request for more information from the U.S. FDA regarding the clinical hold placed on the IND application for this phase I study.The company expects to respond to the FDAs request for information in the second half of 2019.
    • 08 Aug 2018 According to a ZIOPHARM Oncology media release, the company along with its partners, are expected to start this study in the second half of 2018.
    • 18 Jun 2018 According to a ZIOPHARM Oncology media release, Ziopharm, Precigen, Inc. and The University of Texas MD Anderson Cancer Center, the IND sponsor, are seeking to conduct this clinical trial to evaluate CAR+ T cells manufactured with Sleeping Beauty technology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top